DLCG reported Q2 2026 revenue of $24.9M, a 1% increase. The strategic acquisition of Phylogix is projected to contribute $15-$18M in EBITDA in its first year.
DLCG reported Q2 2026 revenue of $24.9 million (CAD), up 1% year-over-year and slightly ahead of the consensus estimate. The company navigated a soft housing market while successfully integrating the strategic acquisition of Phylogix, which is expected to enhance its profitability and market reach.
Key Takeaways
- Funded mortgage volume increased 5% year-over-year to $22.1 billion, driven by improved broker productivity.
- Adjusted EBITDA remained steady at $12.6 million, with margins at 50%, reflecting a disciplined cost structure.
- Net income decreased to $7.1 million, down from $7.7 million in Q2 2025, mainly due to increased share-based payment expenses.
- Phylogix acquisition closed on July 31, contributing approximately $15 to $18 million in adjusted EBITDA for its first full year.
- Direct costs fell 8% year-over-year to 11.9% of revenue, thanks to a realignment of the sales team structure in late 2025.
Revenue Growth Amid Market Challenges
DLCG's revenue rose 1% year-over-year to $24.9 million, showing resilience in a challenging housing environment. Funded mortgage volumes increased by 5% to $22.1 billion, fueled by higher broker productivity. However, the company faced a 4% decline in revenue from its Newton segment, primarily due to a revenue reclassification recorded in Q2 2025. The adjusted EBITDA of $12.6 million remained consistent year-over-year, with margins holding at 50%, signaling stable profitability despite external pressures.
| Metric | Q2 2026 | YoY Change | QoQ Change |
|---|---|---|---|
| Revenue | $24.9M | +1% | N/A |
| Funded Mortgage Volume | $22.1B | +5% | N/A |
| Adjusted EBITDA | $12.6M | 0% | N/A |
| Net Income | $7.1M | -8% | N/A |
Strategic Acquisition of Phylogix
The acquisition of Phylogix marks a pivotal moment for DLCG, enhancing its position in the Canadian mortgage sector. Phylogix, a leading mortgage technology platform, is expected to generate about $15 to $18 million in adjusted EBITDA in its first year, significantly bolstering DLCG's earnings. The transaction was financed through a $62.3 million term facility, ensuring that DLCG retains a strong balance sheet with a debt-to-EBITDA ratio of 0.9 times. This acquisition not only provides immediate financial benefits but also expands access to valuable real-time data in the housing market, crucial for driving future growth.
“We are very excited about Phylogix. This acquisition is extraordinarily accretive long term and gives us real positioning in terms of lender and partner relationships,” said Gary Morris, CEO.
Expense Management Initiatives
In light of a soft housing market, DLCG has initiated a formal expense review program aimed at identifying additional cost-saving opportunities. This review targets all business areas, including HR, technology, and general administrative expenses. While direct costs decreased by 8% year-over-year, the company remains focused on managing its G&A expenses carefully, especially as revenue growth becomes more challenging in the current economic climate.
Analyst Q&A Insights
During the Q&A session, analysts raised questions about the Newton revenue performance and its implications for future growth. Matthew Lee from Canaccord Genuity queried about the flat revenue trend despite an increase in penetration, to which management acknowledged the complexities involved in revenue generation tied to broker performance and negotiation outcomes. CEO Gary Morris also discussed the potential for improved recruitment of brokers due to the Phylogix acquisition, indicating that the ability to offer continuity in technology platforms could ease transitions for brokers considering switching to DLCG.
Frequently Asked Questions
Did DLCG beat earnings estimates in Q2 2026?
Yes, DLCG reported adjusted diluted earnings per share of $0.09, slightly above analyst estimates.
What is the expected impact of the Phylogix acquisition on DLCG's revenue?
The Phylogix acquisition is expected to contribute approximately $15 to $18 million in adjusted EBITDA for its first full year, enhancing overall revenue.
How did direct costs change in Q2 2026 compared to the prior year?
Direct costs decreased by 8% year-over-year, reflecting a reduction from 13.1% of revenue in Q2 2025 to 11.9% in Q2 2026.
What were the main factors affecting net income in Q2 2026?
Net income declined to $7.1 million, primarily due to increased share-based payment expenses and higher general and administrative costs.
In conclusion, DLCG's Q2 2026 results demonstrate a cautious yet strategic approach to navigating challenges within the housing market. The success of the Phylogix acquisition and ongoing expense management will be critical focal points as the company progresses through the remainder of the year.
This analysis is based on public earnings call materials and is not investment advice.
